PSA changes and prostate cancer characteristics and mortality
* In the screening arm of the PLCO trial, assess the association between final assessed Prostate Specific Antigen (PSA) level and prostate cancer specific mortality and all-cause mortality. We will use regression splines to model the continuous relationship between PSA and mortality, as opposed to breaking PSA into (arbitrary) categories.
* Assess whether age (within the range included in PLCO) moderates the relationship between final PSA and prostate cancer specific/all cause mortality.
* Compare PSA trajectory (change across the 5 yearly assessments) between those diagnoses with advanced prostate cancer at initial diagnosis, those with less advanced prostate cancer at initial diagnosis, and those never diagnosed.
Jonathan Shoag, M.D. Urology Institute, University Hospitals Cleveland Medical Center. School of Medicine, Case Western Reserve University
Stephen Rhodes, Ph.D. Urology Institute, University Hospitals Cleveland Medical Center.